Funding for this research was provided by:
Borchard Foundation Center on Law and Aging
Text and Data Mining valid from 2020-01-27
Received: 18 July 2019
Accepted: 10 December 2019
First Online: 27 January 2020
: D.B. Kohn, H.L.M., D.A.W. and A.J.T. are Scientific Advisory Board members, and H.B.G. is Chief Scientific Officer for Orchard Therapeutics. H.B.G. is an employee of and equity/stock holder in Orchard Therapeutics. A.J.T. is an equity/stock holder in Orchard Therapeutics. Orchard Therapeutics has obtained an exclusive option to license from Genethon for the rights and know-how related to the lentiviral vector G1XCGD. C.A.B. and T.P. consult for a sequencing service provider, and C.A.B. consults for Novimmune and SOBI. Eurofins Genomics Sequencing Europe (formerly GATC Biotech AG) is a for-profit company (sequencing service provider). The work performed by Eurofins Genomics Sequencing Europe included in the manuscript is provided to the greater scientific community as a fee-for-service product. E.C.M. reports Advisory Board attendance for Orchard Therapeutics. With regard to interests outside of the submitted work, L.D.W. reports grants from the St. Baldrick’s Foundation, Damon-Runyon Cancer Research Foundation and Alex’s Lemonade Stand Foundation, and personal fees from Magenta Therapeutics. A.J.T. reports Board membership and consultancy with Rocket Pharmaceuticals and Generation Bio, and Board membership with 4BIOCapital. S.-Y.P. reports salary support from Boston Children’s Hospital and a grant from NIH. K.L.S. reports personal fees and non-financial support from Orchard Therapeutics. E.M.K., G.S., M.A., K.F.B., U.C., S.S.d.R., M.J.D., C.Y.K., D.L.-R., C.R., N.I., K.G., K.S., J.D., E.C.M., D.B. Kuhns, J.G., H.R., J.K.E., G.H., P.E.N., F.D.B., M.G., J.X.-B.D. and A.G. declare no competing interests.